Is the promise of more affordable weight loss drugs too good to be true? Compounded semaglutide, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
ConsumerAffairs1d
Here are the health pros and cons of GLP-1RA weight loss drugs
New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...
Chrissy Metz wishes people would stop asking her this 1 question about weight loss
Chrissy Metz of "This Is Us" reveals the lessons she's learned throughout her weight loss journey and from the role she played on the hit show.
Pros and cons of weight-loss jabs
Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...
Gillingham charity boss hails weight-loss injections including Ozempic, Wegovy and Mounjaro as life-changing after dropping 6st in two months
A charity boss who struggled for years to shed pounds despite having undergone surgery has hailed weight-loss jabs as ...
Nature2d
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint bookrunners for the offering.
Healio2d
Top in endocrinology: Metformin plus Mediterranean diet; lean mass loss with GLP-1s
A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with ...
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
SA Asks: What's the most attractive weight-loss stock right now?
While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...
devdiscourse6d
Global Health Front: Innovations, Challenges, and Market Shifts
This summary highlights significant health news, covering topics such as HIV treatment during U.S. aid pauses, Pfizer's diversity program legal settlement, AstraZeneca's halted UK investment, data ...